{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T01:30:56Z","timestamp":1769650256660,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T00:00:00Z","timestamp":1769558400000},"content-version":"vor","delay-in-days":38,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Initiating aripiprazole as antipsychotic monotherapy rather than olanzapine, quetiapine, or risperidone, might prevent\/delay major adverse cardiovascular events (MACEs) over the long-term in people diagnosed with severe mental illness. Using Clinical Practice Research Datalink data, we emulated a trial of aripiprazole versus olanzapine, quetiapine, and risperidone in 20,404 patients 2005\u20132014. Primary outcome was five-year MACE risk (composite of hospitalisation for acute myocardial infarction or stroke and cardiovascular death). Here we show that patients initiating aripiprazole had a similar five-year MACE risk as those initiating olanzapine (risk ratio:\u00a01.03, 95%\u00a0CI, 0.78-1.32), quetiapine (1.02, 95%\u00a0CI, 0.72-1.32), and risperidone (0.88, 95%\u00a0CI, 0.67-1.17). Risk was lower among patients initiating and continuing aripiprazole versus risperidone (0.58, 95%\u00a0CI, 0.39-0.84). For patients at clinical equipoise, antipsychotic selection does not appear to significantly impact risk of the most severe, long-term cardiovascular events. However, further research is needed to replicate our finding of increased risk with continued risperidone use versus aripiprazole.<\/jats:p>","DOI":"10.1038\/s41467-025-67843-w","type":"journal-article","created":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T08:53:55Z","timestamp":1766307235000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of major adverse cardiovascular events with aripiprazole versus olanzapine, quetiapine, and risperidone in severe mental illness: a target trial emulation"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8577-9380","authenticated-orcid":false,"given":"Alvin","family":"Richards-Belle","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4241-938X","authenticated-orcid":false,"given":"Naomi","family":"Launders","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hardoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8645-1942","authenticated-orcid":false,"given":"Kenneth K. C.","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2460-0508","authenticated-orcid":false,"given":"Neil M.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1369-5983","authenticated-orcid":false,"given":"Elvira","family":"Bramon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph F.","family":"Hayes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P. J.","family":"Osborn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,21]]},"reference":[{"key":"67843_CR1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wps.20420","volume":"16","author":"CU Correll","year":"2017","unstructured":"Correll, C. U. et al. Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16, 163\u2013180 (2017).","journal-title":"World Psychiatry"},{"key":"67843_CR2","doi-asserted-by":"publisher","first-page":"e1004520","DOI":"10.1371\/journal.pmed.1004520","volume":"22","author":"A Richards-Belle","year":"2025","unstructured":"Richards-Belle, A. et al. Comparative cardiometabolic safety and effectiveness of aripiprazole in people with severe mental illness: a target trial emulation. PLoS Med. 22, e1004520 (2025).","journal-title":"PLoS Med."},{"key":"67843_CR3","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1002\/wps.21036","volume":"22","author":"A Burschinski","year":"2023","unstructured":"Burschinski, A. et al. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials. World Psychiatry 22, 116\u2013128 (2023).","journal-title":"World Psychiatry"},{"key":"67843_CR4","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","volume":"394","author":"M Huhn","year":"2019","unstructured":"Huhn, M. et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet 394, 939\u2013951 (2019).","journal-title":"Lancet"},{"key":"67843_CR5","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1038\/s41380-021-01334-4","volume":"27","author":"T Kishi","year":"2022","unstructured":"Kishi, T. et al. Pharmacological treatment for bipolar mania: a systematic review and network meta-analysis of double-blind randomized controlled trials. Mol. Psychiatry 27, 1136\u20131144 (2022).","journal-title":"Mol. Psychiatry"},{"key":"67843_CR6","doi-asserted-by":"publisher","first-page":"7698","DOI":"10.1017\/S0033291723001575","volume":"53","author":"A Richards-Belle","year":"2023","unstructured":"Richards-Belle, A., Poole, N., Osborn, D. P. J. & Bell, V. Longitudinal associations between stroke and psychosis: a population-based study. Psychol. Med. 53, 7698\u20137706 (2023).","journal-title":"Psychol. Med."},{"key":"67843_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.euroneuro.2024.07.009","volume":"88","author":"M Solmi","year":"2024","unstructured":"Solmi, M. et al. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: a subanalysis of a systematic review and meta-analysis with meta-regression of moderators. Eur. Neuropsychopharmacol. 88, 6\u201320 (2024).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"67843_CR8","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1192\/bjp.2024.186","volume":"226","author":"A Richards-Belle","year":"2025","unstructured":"Richards-Belle, A. et al. Prescribing of antipsychotics for people diagnosed with severe mental illness in UK primary care 2000\u20132019: 20-year investigation of who receives treatment, with which agents and at what doses. Br. J. Psychiatry 226, 269\u2013277 (2025).","journal-title":"Br. J. Psychiatry"},{"key":"67843_CR9","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/wps.21089","volume":"22","author":"S Leucht","year":"2023","unstructured":"Leucht, S. et al. Long-term efficacy of antipsychotic drugs in initially acutely ill adults with schizophrenia: systematic review and network meta-analysis. World Psychiatry 22, 315\u2013324 (2023).","journal-title":"World Psychiatry"},{"key":"67843_CR10","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.4088\/JCP.13m08642","volume":"74","author":"L Citrome","year":"2013","unstructured":"Citrome, L. et al. Incidence of cardiovascular outcomes and diabetes mellitus among users of second-generation antipsychotics. J. Clin. Psychiatry 74, 1199\u20131206 (2013).","journal-title":"J. Clin. Psychiatry"},{"key":"67843_CR11","doi-asserted-by":"publisher","first-page":"e076268","DOI":"10.1136\/bmj-2023-076268","volume":"385","author":"PLH Mok","year":"2024","unstructured":"Mok, P. L. H. et al. Multiple adverse outcomes associated with antipsychotic use in people with dementia: population based matched cohort study. BMJ 385, e076268 (2024).","journal-title":"BMJ"},{"key":"67843_CR12","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.4088\/JCP.18m12636","volume":"80","author":"LG Taylor","year":"2019","unstructured":"Taylor, L. G., Panucci, G., Mosholder, A. D., Toh, S. & Huang, T.-Y. Antipsychotic use and stroke: a retrospective comparative study in a non-elderly population. J. Clin. Psychiatry 80, 1163 (2019).","journal-title":"J. Clin. Psychiatry"},{"key":"67843_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n, M. A. & Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. Am. J. Epidemiol. 183, 758\u2013764 (2016).","journal-title":"Am. J. Epidemiol."},{"key":"67843_CR14","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1214\/19-AOAS1282","volume":"13","author":"F Li","year":"2019","unstructured":"Li, F. & Li, F. Propensity score weighting for causal inference with multiple treatments. Ann. Appl. Stat. 13, 2389\u20132415 (2019).","journal-title":"Ann. Appl. Stat."},{"key":"67843_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-021-01440-5","volume":"21","author":"E Bosco","year":"2021","unstructured":"Bosco, E., Hsueh, L., McConeghy, K. W., Gravenstein, S. & Saade, E. Major adverse cardiovascular event definitions used in observational analysis of administrative databases: a systematic review. BMC Med. Res. Methodol. 21, 241 (2021).","journal-title":"BMC Med. Res. Methodol."},{"key":"67843_CR16","doi-asserted-by":"publisher","unstructured":"Richards-Belle, A. Risk of major adverse cardiovascular events with aripiprazole versus olanzapine, quetiapine, risperidone: protocol for a target trial emulation study. https:\/\/doi.org\/10.17605\/OSF.IO\/JPCYE (2024).","DOI":"10.17605\/OSF.IO\/JPCYE"},{"key":"67843_CR17","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke, J. P. et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 4, e297 (2007).","journal-title":"PLoS Med."},{"key":"67843_CR18","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1093\/ije\/dyv098","volume":"44","author":"E Herrett","year":"2015","unstructured":"Herrett, E. et al. Data Resource Profile: Clinical Practice Research Datalink (CPRD). Int. J. Epidemiol. 44, 827\u2013836 (2015).","journal-title":"Int. J. Epidemiol."},{"key":"67843_CR19","doi-asserted-by":"publisher","first-page":"1740","DOI":"10.1093\/ije\/dyz034","volume":"48","author":"A Wolf","year":"2019","unstructured":"Wolf, A. et al. Data resource profile: Clinical Practice Research Datalink (CPRD) Aurum. Int. J. Epidemiol. 48, 1740\u20131740g (2019).","journal-title":"Int. J. Epidemiol."},{"key":"67843_CR20","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1093\/ije\/dyx015","volume":"46","author":"A Herbert","year":"2017","unstructured":"Herbert, A., Wijlaars, L., Zylbersztejn, A., Cromwell, D. & Hardelid, P. Data Resource Profile: Hospital Episode Statistics Admitted Patient Care (HES APC). Int. J. Epidemiol. 46, 1093\u20131093i (2017).","journal-title":"Int. J. Epidemiol."},{"key":"67843_CR21","doi-asserted-by":"publisher","unstructured":"Launders, N., Richards-Belle, A., Hardoon, S., Osborn, D. P. J. & Hayes, J. F. PH1649 \/ 3407 - Severe mental illness (SMI). Phenotype Library https:\/\/doi.org\/10.48533\/yb2k-y050 (2024).","DOI":"10.48533\/yb2k-y050"},{"key":"67843_CR22","unstructured":"NHS Business Services Authority. Prescribing Costs in Hospitals and the Community - England 2023-24. (2024). https:\/\/www.nhsbsa.nhs.uk\/statistical-collections\/prescribing-costs-hospitals-and-community-england\/prescribing-costs-hospitals-and-community-england-2023-24."},{"key":"67843_CR23","doi-asserted-by":"publisher","first-page":"f2350","DOI":"10.1136\/bmj.f2350","volume":"346","author":"E Herrett","year":"2013","unstructured":"Herrett, E. et al. Completeness and diagnostic validity of recording acute myocardial infarction events in primary care, hospital care, disease registry, and national mortality records: cohort study. BMJ 346, f2350 (2013).","journal-title":"BMJ"},{"key":"67843_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1097\/EDE.0000000000000688","volume":"28","author":"M Kivim\u00e4ki","year":"2017","unstructured":"Kivim\u00e4ki, M. et al. Validity of cardiovascular disease event ascertainment using linkage to UK Hospital records. Epidemiology 28, 735\u2013739 (2017).","journal-title":"Epidemiology"},{"key":"67843_CR25","doi-asserted-by":"publisher","first-page":"463","DOI":"10.2307\/2529360","volume":"33","author":"WA Thompson","year":"1977","unstructured":"Thompson, W. A. On the treatment of grouped observations in life studies. Biometrics 33, 463\u2013470 (1977).","journal-title":"Biometrics"},{"key":"67843_CR26","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1097\/EDE.0000000000001626","volume":"34","author":"BA Dickerman","year":"2023","unstructured":"Dickerman, B. A., Garc\u00eda-Alb\u00e9niz, X., Logan, R. W., Denaxas, S. & Hern\u00e1n, M. A. Evaluating metformin strategies for cancer prevention: a target trial emulation using electronic health records. Epidemiology 34, 690\u2013699 (2023).","journal-title":"Epidemiology"},{"key":"67843_CR27","first-page":"54","volume":"1","author":"B Efron","year":"1986","unstructured":"Efron, B. & Tibshirani, R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Stat. Sci. 1, 54\u201375 (1986).","journal-title":"Stat. Sci."},{"key":"67843_CR28","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1002\/sim.7654","volume":"37","author":"M Schomaker","year":"2018","unstructured":"Schomaker, M. & Heumann, C. Bootstrap inference when using multiple imputation. Stat. Med. 37, 2252\u20132266 (2018).","journal-title":"Stat. Med"},{"key":"67843_CR29","doi-asserted-by":"publisher","first-page":"S90","DOI":"10.1093\/schbul\/sbv167","volume":"42","author":"S Leucht","year":"2016","unstructured":"Leucht, S., Samara, M., Heres, S. & Davis, J. M. Dose equivalents for antipsychotic drugs: the DDD method. Schizophr. Bull. 42, S90\u2013S94 (2016).","journal-title":"Schizophr. Bull."},{"key":"67843_CR30","doi-asserted-by":"publisher","first-page":"a1227","DOI":"10.1136\/bmj.a1227","volume":"337","author":"IJ Douglas","year":"2008","unstructured":"Douglas, I. J. & Smeeth, L. Exposure to antipsychotics and risk of stroke: self controlled case series study. BMJ 337, a1227 (2008).","journal-title":"BMJ"},{"key":"67843_CR31","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2019.3087","volume":"321","author":"E Juszczak","year":"2019","unstructured":"Juszczak, E., Altman, D. G., Hopewell, S. & Schulz, K. Reporting of multi-arm parallel-group randomized trials: extension of the CONSORT 2010 statement. JAMA 321, 1610\u20131620 (2019).","journal-title":"JAMA"},{"key":"67843_CR32","doi-asserted-by":"publisher","unstructured":"Alvin Richards-Belle. Alvin-RB\/antipsychotics_mace_cprd: Version 1 Zenodo https:\/\/doi.org\/10.5281\/ZENODO.17236638 (2025).","DOI":"10.5281\/ZENODO.17236638"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67843-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67843-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67843-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:29:58Z","timestamp":1769606998000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-67843-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,21]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["67843"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-67843-w","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,21]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"JFH has received consultancy fees from Wellcome Trust, juli Inc and Swiss Re unrelated to the results of the current study. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1083"}}